This is an important and high-anxiety week for investors, as many very large companies report much-anticipated EPS -- including Tesla (which popped on results after the close on Tuesday), Meta on Wednesday, and Microsoft and Alphabet on Thursday. On Friday morning, the Federal Reserve's favored inflation metric, the PCE report, hits the tape with March data.

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Our list this week shines a light on international stocks. We sorted our database for large-cap international stocks valued above $50 billion and with a High or Medium-High Argus rating for Financial Strength. We then sorted further, looking for stocks in the group that are furthest from their 52-week high, suggesting value. Timing matters, of course, and stocks have been on a tear lately. We ran the same list a month ago and note some shifting today. Roche Holding was on our initial list, but we have since downgraded it to a HOLD. Novo Nordisk has had tremendous attention from investors, but was not on our previous list as it was hitting new highs -- and has fallen from those highs in the past few weeks. Here is our current list of Argus large-cap BUY-rated international stocks that seem to offer value.

We don't want to get too excited about the Russell 2000 (IWM $208), but the index is pushing up against key chart resistance once again. IWM is poking its head above prior highs seen in 12/2023, 3/2022, and the January 2022 breakdown level near $207. Since that breakdown over two years ago, IWM has traded in a volatile range, with the bottom down at $160.